Dangshe Ma
Senior Director Regeneron Pharmaceuticals
I am a Senior Director at Regeneron Pharmaceuticals, where I lead a team focused on Antibody Radionuclide Conjugates (ARC) for targeted imaging and therapeutic applications. I earned my Ph.D. in Radiopharmaceutical Chemistry from the University of Missouri–Columbia and completed postdoctoral training at Memorial Sloan Kettering Cancer Center, where I contributed to pioneering work on DOTA chelation for Ac-225 and co-authored a 2001 Science paper describing the in vivo Ac-225/Bi-213 nanogenerator.
Throughout my career at Progenics, Pfizer, and Regeneron, I have advanced antibody-based therapies—including Antibody-Drug Conjugates (ADC) and ARC—from early research into clinical development.
Seminars
Wednesday 2nd December 2026
Panel Discussion: Why Are Big Pharma Betting on Targeted Radiopharmaceuticals?
5:00 pm
- Exploring the scientific, clinical and commercial factors driving increasing investment into targeted radiopharmaceuticals from large pharmaceutical companies
- Comparing the evolution of the radiopharmaceutical landscape with the rapid growth of antibody-drug conjugates and identifying the key lessons that can be applied across modalities
- Debating whether radiopharmraceuticals are approaching a similar inflection point to ADCs and what challenges still need to be overcome to unlock broader adoption
